Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Abbv-453: A Highly Potent and Selective Next Generation Small Molecule Inhibitor of BCL-2

Darren C Phillips, Luzivette Robles-Cardona, Cory Alvey, Justin Ingram, Lloyd T Lam, Ziping Yang, Jacob J Riehm, Jun Chen, Matthew Kurnick, Peter Kovar, Jin Wang, George Doherty, Vikram Bhat, Yujia Dai, Andrew Judd, Andrew Souers

Blood (2024) 144 (Supplement 1): 4966.

https://doi.org/10.1182/blood-2024-205998

Published: 2024

Journal Articles

Anti-Leukemia Combinatorial Efficacy of ABBV155, a B7H3-BCL-XL Inhibitor Antibody-Drug Conjugate, in Combination with Venetoclax through BCL-XL/BIM and BCL-2/BIM Complex Dissociations

Zhe Wang, Cassandra L. Ramage, Helen Ma, Haichao Zhang, Andrew Souers, Darren C Phillips, Marina Konopleva, Qi Zhang Tatarata

Blood (2024) 144 (Supplement 1): 2760.

https://doi.org/10.1182/blood-2024-193405

Published: 2024

Journal Articles

MALT1 Protease Inhibition Overcomes BTK Inhibitor Resistance and Shows Synergistic Activity with Venetoclax in Models of B Cell Lymphoma and Leukemia

Joshua Plotnik, Velitchka Bontcheva, Colleen Dowell, Christine Will, Jun Chen, Adam Richardson, Ryan McClure, Paul Jung, Lan Pham, Andrew Souers, Jonathan Meulbroek, William Pappano

Blood (2023) 142 (Supplement 1): 5009.

https://doi.org/10.1182/blood-2023-189061

Published: 2023

Journal Articles

Identification of Recurrent Genomic Alterations in the Apoptotic Machinery in CLL Patients Treated with Venetoclax Monotherapy

Brenda J Chyla, PhD, Relja Popovic, PhD, Charles Lu, PhD, Fengjiao Dunbar, PhD, Danjuma Quarless, PhD, Kenneth Robinson, MS, Scott Warder, PhD, Amanda Jacobson, PhD, Lang Zhou, PhD, Andrew Souers, PhD, Jeffrey Waring, PhD, Anahita Bhathena, PhD, Joel D. Leverson, PhD, Su Young Kim, MD PhD

Blood (2019) 134 (Supplement_1): 172.

https://doi.org/10.1182/blood-2019-127458

Published: 2019

Journal Articles

FLT3-ITD Activation Mediates Resistance to the BCL-2 Selective Antagonist, Venetoclax, in FLT3-ITD Mutant AML Models

Raghuveer Singh Mali, PhD, Elisabeth A. Lasater, PhD, Kelly Doyle, Ritu Malla, Erwin Boghaert, Andrew Souers, Joel D. Leverson, PhD, Deepak Sampath, PhD

Blood (2017) 130 (Supplement 1): 1348.

https://doi.org/10.1182/blood.V130.Suppl_1.1348.1348

Published: 2017

NARROW

Abbv-453: A Highly Potent and Selective Next Generation Small Molecule Inhibitor of BCL-2

Anti-Leukemia Combinatorial Efficacy of ABBV155, a B7H3-BCL-XL Inhibitor Antibody-Drug Conjugate, in Combination with Venetoclax through BCL-XL/BIM and BCL-2/BIM Complex Dissociations

MALT1 Protease Inhibition Overcomes BTK Inhibitor Resistance and Shows Synergistic Activity with Venetoclax in Models of B Cell Lymphoma and Leukemia

Identification of Recurrent Genomic Alterations in the Apoptotic Machinery in CLL Patients Treated with Venetoclax Monotherapy

FLT3-ITD Activation Mediates Resistance to the BCL-2 Selective Antagonist, Venetoclax, in FLT3-ITD Mutant AML Models

Email alerts

ASH Publications

American Society of Hematology

Abbv-453: A Highly Potent and Selective Next Generation Small Molecule Inhibitor of BCL-2

Anti-Leukemia Combinatorial Efficacy of ABBV155, a B7H3-BCL-XL Inhibitor Antibody-Drug Conjugate, in Combination with Venetoclax through BCL-XL/BIM and BCL-2/BIM Complex Dissociations

MALT1 Protease Inhibition Overcomes BTK Inhibitor Resistance and Shows Synergistic Activity with Venetoclax in Models of B Cell Lymphoma and Leukemia

Identification of Recurrent Genomic Alterations in the Apoptotic Machinery in CLL Patients Treated with Venetoclax Monotherapy

FLT3-ITD Activation Mediates Resistance to the BCL-2 Selective Antagonist, Venetoclax, in FLT3-ITD Mutant AML Models

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only